Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Expression of HER2/erbB-2 correlates with survival in osteosarcoma.

Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, Meyers PA.

J Clin Oncol. 1999 Sep;17(9):2781-8.

PMID:
10561353
2.

Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma.

Morris CD, Gorlick R, Huvos G, Heller G, Meyers PA, Healey JH.

Clin Orthop Relat Res. 2001 Jan;(382):59-65.

PMID:
11154005
3.

Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.

Ferrari S, Bertoni F, Zanella L, Setola E, Bacchini P, Alberghini M, Versari M, Bacci G.

Cancer. 2004 May 1;100(9):1936-42.

4.

Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.

Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE, Krailo M, Devidas M, Barkauskas DA, Siegal GP, Ferguson WS, Letson GD, Marcus K, Goorin A, Beardsley P, Marina N.

J Clin Oncol. 2012 Jul 10;30(20):2545-51. doi: 10.1200/JCO.2011.37.4546. Epub 2012 Jun 4.

5.

HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study.

Gorlick S, Barkauskas DA, Krailo M, Piperdi S, Sowers R, Gill J, Geller D, Randall RL, Janeway K, Schwartz C, Grier H, Meyers PA, Gorlick R, Bernstein M, Marina N.

Pediatr Blood Cancer. 2014 Sep;61(9):1558-64. doi: 10.1002/pbc.25074. Epub 2014 Apr 22.

6.

The Prognostic Role of Ezrin and HER2/neu Expression in Osteosarcoma.

Abdou AG, Kandil M, Asaad NY, Dawoud MM, Shahin AA, Abd Eldayem AF.

Appl Immunohistochem Mol Morphol. 2016 May-Jun;24(5):355-63. doi: 10.1097/PAI.0000000000000197.

PMID:
26067138
7.

Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma.

Kilpatrick SE, Geisinger KR, King TS, Sciarrotta J, Ward WG, Gold SH, Bos GD.

Mod Pathol. 2001 Dec;14(12):1277-83.

8.

Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma.

Baumhoer D, Smida J, Specht K, Bink K, Quintanilla-Martinez L, Rosemann M, Siggelkow H, Nathrath WB, Atkinson MJ, Bielack S, Jundt G, Nathrath M.

Hum Pathol. 2011 Jun;42(6):859-66. doi: 10.1016/j.humpath.2010.09.016. Epub 2011 Feb 2.

PMID:
21292304
9.

Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.

Scotlandi K, Manara MC, Hattinger CM, Benini S, Perdichizzi S, Pasello M, Bacci G, Zanella L, Bertoni F, Picci P, Serra M.

Eur J Cancer. 2005 Jun;41(9):1349-61.

PMID:
15913990
10.

Expression of molecular markers in the tumor and survival prognosis in osteosarcoma.

Boulytcheva IV, Soloviev YN, Kushlinskii NE, Mahson AN.

Bull Exp Biol Med. 2010 Dec;150(2):237-42. English, Russian.

PMID:
21240382
11.
12.

Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma.

Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L.

Clin Cancer Res. 2002 Mar;8(3):788-93.

13.

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.

Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.

Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8.

PMID:
23749689
14.

C-erbB-2 expression and prognostic significance in osteosarcoma.

Yalçin B, Gedikoğlu G, Kutluk T, Varan A, Akyüz C, Büyükpamukçu M.

Pediatr Blood Cancer. 2008 Aug;51(2):222-7. doi: 10.1002/pbc.21576.

PMID:
18421709
15.

Interferon-α/β receptor as a prognostic marker in osteosarcoma.

Kubo T, Shimose S, Matsuo T, Fujimori J, Arihiro K, Ochi M.

J Bone Joint Surg Am. 2011 Mar 16;93(6):519-26. doi: 10.2106/JBJS.J.00198.

PMID:
21411701
16.

ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma.

Onda M, Matsuda S, Higaki S, Iijima T, Fukushima J, Yokokura A, Kojima T, Horiuchi H, Kurokawa T, Yamamoto T.

Cancer. 1996 Jan 1;77(1):71-8.

17.

Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.

Jeon DG, Song WS, Cho WH, Kong CB, Cho SH.

Clin Orthop Relat Res. 2014 Jun;472(6):1911-20. doi: 10.1007/s11999-014-3521-1. Epub 2014 Feb 27.

18.

Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma.

Akatsuka T, Wada T, Kokai Y, Sawada N, Yamawaki S, Ishii S.

Oncology. 2001;60(4):361-6.

PMID:
11408805
19.

Prognostic factors in non-metastatic limb osteosarcoma: A 20-year experience of one center.

Tomer G, Cohen IJ, Kidron D, Katz K, Yosipovitch Z, Meller I, Zaizov R.

Int J Oncol. 1999 Jul;15(1):179-85.

PMID:
10375613
20.

Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol.

Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, Healey JH.

J Clin Oncol. 1998 Jul;16(7):2452-8.

PMID:
9667263

Supplemental Content

Support Center